Key result
Collaborative cardio-oncology care optimizes early detection and management of cancer therapy cardiotoxicity.
Why the study?
The emergence of cardiovascular events during cancer treatment poses diagnostic challenges and worsens prognosis, requiring improved early cardiotoxicity markers and prevention methods.
Cardiotoxicity during cancer therapy may worsen prognosis; leaves open optimal early markers and prevention strategies.
Cardiovascular diseases (CVD) and cancers are the leaders in their prevalence and the major causes of death in economically developed countries, determining their high sociomedical significance in society. Improvement of methods for the early diagnosis and treatment of cancers has contributed to increases in relapse-free survival and life expectancy in these patients. At the same time, the new problems have emerged particularly in the development of various cardiovascular events/diseases when treating cancer, which may predict worse prognosis in patients and be an independent cause of death. To search for new markers of cardiotoxicity at early stages and to develop effective methods for the prevention and personalized treatment of cancer and CVD are the problems that can be solved only by joint efforts of cardiologists and oncologists.
No takes yet. Share an insight, caveat, or question.
Chazova et al. (2015) conducted a review in Cardiovascular diseases and cancers. Chemo- and radiation therapy was evaluated. Cardiotoxic effects of chemo- and radiation therapy in cancer treatment require joint efforts of cardiologists and oncologists for early diagnosis, prevention, and personalized management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: